Condition (MeSH)
Locked-In Syndrome
ClinicalTrials.gov lists 19 trials for Locked-In Syndrome or a narrower condition beneath it. VA Office of Research and Development has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
19 of the 19 trials are tagged with Locked-In Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Locked-In Syndrome trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 2 |
| 2017 | 3 |
| 2016 | 1 |
| 2015 | 1 |
| 2013 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Locked-In Syndrome trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Not applicable | 18 |
| Observational | 1 |
How many Locked-In Syndrome trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 6 |
| Enrolling by invitation | 1 |
| Completed | 4 |
| Terminated | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Locked-In Syndrome trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| VA Office of Research and Development | 1 |
Which serious adverse events do Locked-In Syndrome trials report? (6)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| disease related respiratory failure | 2 | 1 |
| pneumonia | 2 | 1 |
| Hypotension | 1 | 1 |
| fever | 1 | 1 |
| low oxygen | 1 | 1 |
Showing 5 of 6 adverse events.
Which publications cover Locked-In Syndrome? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The challenge of controlling an auditory BCI in the case of severe motor disability. | Journal of neuroengineering and rehabilitation | 2024 | Yes |
| Using fMRI to localize target regions for implanted brain-computer interfaces in locked-in syndrome. | Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology | 2023 | Yes |
| Dorsolateral prefrontal cortex-based control with an implanted brain-computer interface. | Scientific reports | 2020 | Yes |
| New and emerging access technologies for adults with complex communication needs and severe motor impairments: State of the science. | Augmentative and alternative communication (Baltimore, Md. : 1985) | 2019 | No |
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Locked-in syndrome | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Locked-in syndrome | Cases families | Worldwide | Not stated | Exact | |
| Locked-in syndrome | Cases families | Worldwide | Not stated | Unspecified | |
| Locked-in syndrome | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Unspecified |
| Locked-in syndrome | Cases families | Worldwide | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Locked-in syndrome | 2406 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Locked-in syndrome | 2406 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: drugs tested and sub-conditions in mesh.